Stockscreener 앱 받기
2.48
4.98%
-0.13
시간 외 거래:
2.50
0.02
+0.81%
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Aardvark Therapeutics (Nasdaq: AARD) grants inducement options totaling 88,217 shares - Stock Titan
Xilio Therapeutics (Nasdaq: XLO) grants inducement option at $0.7967 with 10-year term - Stock Titan
Karyopharm (Nasdaq: KPTI) grants 800 RSUs to new hire, vesting over 3 years - Stock Titan
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics Inc. stock trend forecastNew Guidance & High Accuracy Trade Signal Alerts - newser.com
Volatility clustering patterns for C4 Therapeutics Inc.Earnings Overview Summary & Safe Entry Point Identification - newser.com
Will earnings trigger a reversal in C4 Therapeutics Inc.Product Launch & Low Risk Investment Opportunities - newser.com
C4 Therapeutics Inc Stock Analysis and ForecastSupport Zone Identification & Investor Community Interactions - earlytimes.in
C4 Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in C4 The - GuruFocus
How strong is C4 Therapeutics Inc. stock balance sheet2025 Buyback Activity & Technical Pattern Based Buy Signals - fcp.pa.gov.br
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
What hedge fund activity signals for C4 Therapeutics Inc. stockMarket Movers & Low Drawdown Investment Ideas - fcp.pa.gov.br
Ptc therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
C4 Therapeutics Inc. stock retracement – recovery analysisMarket Performance Summary & Proven Capital Preservation Tips - newser.com
How C4 Therapeutics Inc. stock benefits from strong dollarJuly 2025 Market Mood & Safe Entry Point Alerts - newser.com
Full technical analysis of C4 Therapeutics Inc. stockQuarterly Profit Report & Real-Time Volume Analysis Alerts - newser.com
C4 Therapeutics (NASDAQ:CCCC) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
How C4 Therapeutics Inc. stock reacts to oil pricesEarnings Overview Summary & Community Consensus Picks - newser.com
C4 Therapeutics (CCCC) Expected to Announce Earnings on Thursday - MarketBeat
Applying chart zones and confluence areas to C4 Therapeutics Inc.2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Live market analysis of C4 Therapeutics Inc.2025 Sector Review & Fast Exit/Entry Strategy Plans - newser.com
Candlestick signals on C4 Therapeutics Inc. stock todayJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Will C4 Therapeutics Inc. stock benefit from commodity pricesEarnings Risk Report & Low Risk High Win Rate Stock Picks - Trung tâm Dự báo KTTV quốc gia
Will C4 Therapeutics Inc. stock maintain momentum in 20252025 Price Targets & Community Consensus Trade Alerts - Trung tâm Dự báo KTTV quốc gia
CEO Moves: Will C4 Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Analysis & Weekly Consistent Profit Watchlists - Trung tâm Dự báo KTTV quốc gia
C4 Therapeutics Lines Up $125 Million To Fund Cancer Trials - Finimize
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
C4 Therapeutics Announces Stock and Warrants Offering - TipRanks
Revenues Working Against C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Share Price Following 38% Dive - 富途牛牛
C4 Therapeutics (CCCC) to Raise $125M Through Stock and Warrant Offering - GuruFocus
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering - Investing News Network
C4 Therapeutics, Inc. Announces $125 Million Underwritten Offering to Advance Cemsidomide Multiple Myeloma Development - Quiver Quantitative
$125M Upfront — C4 Therapeutics Prices Offering to Fund Cemsidomide Trials; May Reach $349.7M - Stock Titan
0.64%
0.35%
자본화:
|
볼륨(24시간):